MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
MacroGenics Financial Update: MacroGenics has entered a royalty purchase agreement with Sagard Healthcare Partners, receiving a $70 million upfront payment which extends its cash runway through the first half of 2027, supporting ongoing clinical programs.
ZYNYZ Overview: ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by MacroGenics and marketed by Incyte, is indicated for certain cancer treatments in adults, with continued approval contingent on further clinical trials.
Trade with 70% Backtested Accuracy
Analyst Views on MGNX
About MGNX
About the author
After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports
MacroGenics Earnings Report: MacroGenics, Inc. saw a 10.2% increase in after-hours trading, reporting a third-quarter net income of $16.8 million, down from $56.3 million year-over-year, with revenue falling to $72.8 million.
SELLAS Life Sciences Update: SELLAS Life Sciences Group, Inc. rose 9.4% after narrowing its quarterly net loss to $6.8 million, with cash and equivalents reported at approximately $44.3 million as of September 30, 2025.
KORU Medical Systems Performance: KORU Medical Systems, Inc. gained 8.47% after reporting a narrower net loss of $0.8 million and a 27.2% revenue increase to $10.4 million, while raising its full-year revenue guidance.
Wave Life Sciences Results: Wave Life Sciences Ltd. increased by 5.68% after reporting a third-quarter net loss of $53.9 million, an improvement from the previous year, with revenue of $7.6 million.
MacroGenics Revenue Doubles in Q2
Financial Performance: MacroGenics reported Q2 2025 GAAP revenue of $22.2 million, significantly below the $31.7 million analyst estimate, with a loss per share of $(0.57), missing expectations as well. The company highlighted lower operating costs but faced challenges due to the absence of product sales after exiting its previous marketed product.
Strategic Focus and Pipeline: The company is shifting its focus to research-stage pipeline candidates, emphasizing partnerships and cost management while maintaining sufficient funds through mid-2027. Key upcoming milestones include clinical results for its lead candidate lorigerlimab and potential regulatory approvals for collaborations that could yield significant payments.
